Agile Therapeutics (AGRX) M&A Announcement summary

Deal rationale and strategic fit

• Acquisition expands Insud Pharma's US presence and strengthens its women's health and contraceptive portfolio through Exeltis USA.

• Agile's Twirla product complements Insud's offerings, targeting unmet needs in women's contraception.

Financial terms and conditions

• Agile shareholders receive $1.52 per share in cash, net of assumed liabilities and estimated transaction costs.

• Total enterprise value of the transaction is approximately $45 million.

• Agile common stock will be delisted from the OTC QB and will no longer be publicly traded.

Integration plans and timeline

• Agile merges with an indirect, wholly owned Insud subsidiary and continues as an indirect Insud subsidiary.

• The acquisition was approved by Agile shareholders on August 22, 2024, and completed on August 26, 2024.